免疫抑制/免疫调节治疗的皮肤病患者的新冠疫苗接种建议（国际皮肤性病学联盟学会）
Recommendations for COVID Vaccination for Dermatological Patients on Immunosuppressive/Immunomodulatory Therapy (IADVL Academy).
作者信息
Munisamy Malathi, Singh Bhabani S T P, Pandhi Deepika
机构信息
Department of Dermatology and STD, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.
Department of Dermatology, IMS and SUM Hospital, Bhubaneswar, Odisha, India.
出版信息
Indian Dermatol Online J. 2021 Nov 25;12(Suppl 1):S4-S11. doi: 10.4103/idoj.idoj_412_21. eCollection 2021 Nov.
Significant proportion of patients with dermatological disorders are on immunosuppressive or immunomodulatory therapy predisposing them to risk of acquisition of COVID-19 infection. However, the efficacy of COVID-19 vaccination among these patients is a matter of concern due to lack of adequate evidence for their protective effect owing to the drug induced immunosuppressed state. Hence, we from the IADVL academy have framed the recommendations to be followed for COVID-19 vaccination among dermatological patients on immunosuppressive therapy based on available related literature.
相当一部分患有皮肤病的患者正在接受免疫抑制或免疫调节治疗，这使他们有感染新冠病毒的风险。然而，由于药物引起的免疫抑制状态，缺乏足够证据证明新冠疫苗对这些患者的保护作用，因此这些患者接种新冠疫苗的效果令人担忧。因此，我们印度皮肤科医师协会（IADVL）学院根据现有相关文献，制定了免疫抑制治疗的皮肤病患者接种新冠疫苗应遵循的建议。
Zotero 插件